Background Fast-growing melanomas are thought to be responsible for the stable incidence of thick melanomas. It
Introduction
Cutaneous melanomas evolve through clinically and histopathologically discernible progression steps. Transformed melanocytes spread first horizontally above the epidermal basement membrane (radial growth phase), then invade the papillary dermis and eventually extend vertically into the deeper dermis (vertical growth phase).
1,2 These steps can evolve with different growth rates and different biological aggressiveness. In the last years, patient interview-based studies have identified fast-growing melanomas with rapid vertical growth and poor prognosis. [3] [4] [5] Moreover, fastgrowing melanomas with limited opportunities of early detection are thought to be responsible for the stable incidence of thick melanomas, although the median melanoma thickness has decreased over the last decades. [6] [7] [8] [9] To date, it remains unclear whether fast vertical growth ab initio or diagnostic delay is the major determinant for thick melanomas. Clarification of this issue is crucial for the development of effective intervention strategies in terms of secondary prevention of thick melanomas.
In this study, we analysed a cohort of 2253 melanoma patients with prospectively documented follow-up examinations and sought to estimate the impact of follow-up examinations on the incidence of thick second primary melanomas (SPMs). We hypothesized that this setting allows particularly for early detection of melanomas with slow or intermediate growth rate but not for thick melanomas with rapid vertical growth from the outset. 5, 6, 9 Materials and methods
Study population
Between 1 January 2002 and 31 December 2006, 2500 patients of the Department of Dermatology of the University Hospital Tuebingen were diagnosed with primary malignant melanoma and recorded in the nationwide German Central Malignant Melanoma Registry after obtaining informed written consent. The Department of Dermatology Tuebingen performs melanoma follow-up cooperatively with local dermatologists, and it has been agreed that any patient who is diagnosed with an invasive melanoma in Tuebingen should be referred to the University Hospital Tuebingen.
At the initial consultation at the Department of Dermatology, patients were extensively educated regarding the clinical characteristics of melanoma and its metastases, emphasizing the role of self-examination and the recognition of signs of recurrence. Each follow-up appointment consisted of a complete history, total body skin examination, palpation of the scar of primary resection, in-transit route and draining lymph nodes. Intervals of the physical examinations, imaging studies and blood testing were performed according to the guidelines of the German Society of Dermatology which remained rather constant over time (Table S1-S3) . When patients were recorded in the German Malignant Melanoma Registry, all melanomas were reviewed by experienced dermatopathologists of the Department of Dermatology. Exceptions only applied for histopathology reports from selected and experienced external dermatopathologists. In general, follow-up examinations were alternated every other examination between the Department of Dermatology Tuebingen and dermatology practices. However, stage IA patients were often seen exclusively by local dermatologists and stage IV patients exclusively in the Department of Dermatology Tuebingen. If follow-up was performed at patients' local dermatologists, doctors were provided with follow-up sheets for documentation of their findings (total body skin examination, ultrasound scans of regional lymph nodes, tumour marker S100b, histopathologic report of excisions). Results of follow-up examinations were prospectively documented, and this study was approved by the ethics board of the University Hospital Tuebingen.
After definition of further inclusion criteria (follow-up time of at least 3 months, invasive primary cutaneous melanoma with known Breslow thickness), a total of 2254 patients and 150 second primary melanomas were identified. We did not include noninvasive first primary melanomas in our analysis as followup was not routinely performed in these patients. However, noninvasive SPMs (Clark level I) were included into the analysis.
Histopathologic reports and computerized medical records of all patients with SPMs (n = 150) were manually reviewed, and four patients were identified with misdiagnosis of SPMs and violation of the inclusion criteria, respectively: The first primary melanoma (FPM) of one patient was diagnosed before 1 January 2002. One patient had a local recurrence of the primary melanoma, one patient received two surgeries for complete resection of the primary tumour, and one patient had a local recurrence of a previously incompletely excised cutaneous metastasis. In total, 146 (6.5%) of 2253 patients developed SPMs until 25 April 2013, 365 patients died and 1022 (44.4 %) were lost to followup during their 10-year follow-up period.
Second primary melanomas that were diagnosed synchronously with the FPM or within the first 30 days after the FPM were referred to as 'synchronous SPMs' and all other SPMs were referred to as 'metachronous SPMs'. In patients with synchronous second and third primary melanomas, the thicker tumour was considered the SPM. In one patient, whose melanoma was initially biopsied and excised completely 11 months later, the melanoma growth rate was estimated by measuring the increase in Breslow thickness between the two surgical procedures. 
Statistics

Results
During follow-up (median 73 months, IQR 41-95) of the study population (n = 2253), a total of 146 patients (6.5%) developed SPMs. Almost half of all SPMs (47.9%, n = 70) were detected in the first year of follow-up and 26.7% synchronously in the first 30 days (Fig. 1) . Of 146 patients with SPMs, 21 (14.4%) developed three primary melanomas, five patients (3.4%) developed four primary melanomas and two patients (1.4%) developed five primary melanomas. Patients with SPMs were older at excision of their first primary melanoma (FPM) as compared to patients without SPMs (61 years, IQR 51-67 vs. 56 years, IQR 43-67; P = 0.005) but primary tumour characteristics did not differ between both groups (Table 1) . Moreover, men (60 years, IQR 48-68) were older at FPM diagnosis than women (52 years, IQR 40-66; P < 0.001). Patients with synchronous SPMs (diagnosis within 30 days after the FPM) were excluded from all further analyses in this study as these melanomas were most likely already present when the FPM was diagnosed.
Comparison of first and second primary melanomas Table 2 compares first and second primary melanomas of patients with metachronous second primary melanomas. FPMs were more often ulcerated (15.0% vs. 0.9%; P < 0.001) and thicker than SPMs (23.4% >2.00 mm vs. 2.8% >2.00 mm; P < 0.001). Invasive FPMs were twice as thick as invasive FPMs (0.80 mm, IQR 0.50-2.00 vs. 0.40 mm, IQR 0.28-0.75; P < 0.001), and nearly one-third (29.9%) of SPMs were in situ melanomas. Superficial spreading melanoma (SSM) was the most common subtype with a higher proportion in SPMs (79.4% vs. 64.5%) and none of the SPMs was of nodular subtype as compared to 16.8% of FPMs (P < 0.05). Overall, first and second primary melanomas were similarly distributed on the body (P = 0.67) and the median time till occurrence of metachronous SPMs was 31 months (IQR 10-60) after the FPM. Table 3 shows the associations between thick (>1.00 mm) and thin SPMs (≤1.0 mm) with clinic-pathologic characteristics. Thick SPMs (median 1.50 mm; min 1.02, max 4.00 mm) comprised 14.0% (n = 15) of all metachronous SPMs and were frequently associated with rare histopathologic subtypes (others than SSM and lentigo maligna melanoma (LMM) 33.3% vs.
Characterization and comparison of thin and thick SPMs
4.3%; P = 0.001). There was a trend that thick SPMs were more often ulcerated than thin SPMs, occurred more often in men and the head and neck area, were diagnosed somewhat later after FPM diagnosis as compared to thin SPMs, had a longer latency to the last follow-up examination and a higher rate of irregular follow-up. However, these differences did not reach statistical significance. Moreover, Breslow thickness of the respective FPMs was similar in both groups (median 0.80 mm). Number of patients
Years after primary melanoma diagnosis
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Clinic-pathologic characteristics of thick SPMs
Follow-up records of all 15 patients with thick SPMs were reviewed to analyse their clinic-pathologic characteristics (Table 4) . Overall, six SPMs were clinically misdiagnosed as non-melanocytic or benign lesions due to their atypical clinical appearance, four of them as basal cell carcinomas. Three SPMs had uncommon histopathologic subtypes (desmoplastic, nevoid and dermal melanoma), and another three SPMs were amelanotic and minimally pigmented, respectively. Fast-growing melanomas as defined by melanomas with vertical growth rates of at least 0.5 mm/month could be definitely excluded in two patients: tumour thickness of patient 4 increased 1.14 mm in 11 months and patient 7 was diagnosed with a 1.50 mm amelanotic secondary nodular SSM that has been clinically misdiagnosed as basal cell carcinoma 3.5 months prior to excision. The thickest SPM was diagnosed in a patient with locoregional advanced disease 38 months after the last documented followup examination.
Discussion
It has been suggested that the intrinsic growth rate rather than diagnostic delay is the major determinant for thick melanomas and that campaigns for early diagnosis are unlikely to have a major impact on prognosis. 10 This hypothesis is challenged by the present study which demonstrates that aggressive vertical growth is not a hallmark of early-stage melanomas and that regular total body skin examinations, as recommended by the German Society of Dermatology, can effectively prevent the occurrence of thick SPMs.
Up to 8% of all melanoma patients develop multiple primary melanomas. 11 Primary tumour and patient characteristics in our study were well balanced between patients with and without SPMs except for age. This suggests that patients with SPMs do not develop less aggressive melanomas than patients with single primary melanomas. These findings are in line with earlier reports 11, 12 and the work of Hwa et al. 13 who could further demonstrate that the biology of primary tumours, as measured by the presence or absence of mitoses, did not differ between patients with and without SPMs. This observation is important as patients with SPMs are known to have a higher density of common 14 and dysplastic nevi 11 and some studies 15, 16 have highlighted that thick and aggressive melanomas develop more often in patients with low nevus count. However, this correlation could not be confirmed by other studies 17 including two studies investigating risk factors for fast growing melanomas. 4, 5 Liu et al. 4 investigated characteristics of rapidly growing melanomas and found that higher tumour thickness, older age, fewer freckles and symmetry of the lesion but not mitotic rate, nevus count, gender, amelanosis and histopathologic subtype remained as independent associations in an overall multivariate linear regression model. The low incidence of thick and ulcerated SPMs 11,18-24 and the high rate of SPMs that were diagnosed synchronously or within the first year of follow-up in our study is consistent with the previous reports. 11, 25, 26 For instance, 21% of FPMs but only 3% of SPMs were thicker than 2.00 mm in a study at the Memorial Sloan-Kettering Cancer Center. 11 These results suggest that many SPMs are probably already (sub)clinically present at excision of the FPM and are early diagnosed during follow-up. Strikingly, none of the SPMs in our study was of nodular subtype. This finding is remarkable as the overall incidence of thick primary melanomas has been stable for decades despite national screening and educational efforts and a fast-growing melanoma subtype, often referred to as nodular melanoma (NM), is thought to be responsible for an unchanged melanoma mortality. [4] [5] [6] [7] [8] [9] According to Clark, NMs grow vertically from the outset in the absence of a radial growth phase and without evidence of intraepidermal growth beyond the width of three rete ridges on either side. 27, 28 However, the current classification of cutaneous melanoma into the subtypes SSM, LMM, NM and ALM has been criticized for several reasons 2, 29 : multivariate regression models have failed to reveal differences in prognosis of the four major subtypes if melanoma thickness was taken into account. 30, 31 Already in 1980, Ackerman proposed a unifying concept of malignant melanoma as all melanomas would evolve in a similar way: melanomas spread first horizontally and may eventually extend vertically into the dermis. NMs are the same except that they enter the vertical growth phase upon a briefer horizontal growth phase. 2 Considering that NMs are virtually never found to be Clark level II, 27,32 Heenan 33, 34 concluded that NM is not a distinct disease entity but rather a common end stage of other histopathologic subtypes. This concept is further corroborated by studies of Bastian who showed distinct patterns of somatic genetic alterations in melanomas on skin with and without chronic sun-induced damage, mucosal and acral melanomas and demonstrated that NMs clustered with these groups but did not have features of an own entity. 35 Moreover, genetic studies have highlighted the necessity of multiple independent mutations in melanoma evolution and have shown that activating mutations of the Mitogen-Activated Protein Kinase pathway and pigmentation. 22 Furthermore, numerous studies have consistently shown that in particular elderly patients, men and patients without physical screening in the last years present with thick and advanced melanomas. 4, 5, 17, 38 So far, the initial growth phase of melanomas has not been elucidated in detail and previous studies investigating the kinetics of melanoma growth were limited by the assumption that melanomas are invasive from the outset and that the rate of growth is constant over time. [3] [4] [5] Moreover, the calculated growth rate of patient interview-based studies solely depends on patient recall and perception that are highly subjective. 3 A more objective approach was used by Lin et al. 39 who calculated the growth rate of 51 initially misdiagnosed melanomas by measuring the increase in melanoma thickness between two sequential biopsies. Of 34 melanomas that were in the in situ phase when the initial biopsy was obtained, 11 were still in the in situ phase when the second biopsy was performed. Melanomas that progressed from the in situ phase to invasive tumours exhibited a low median vertical growth rate of 0.04 mm/month. Similarly, Guerry et al. 1 found that at least 87% of 697 investigated primary melanomas exhibited a radial growth phase and estimated that this growth phase had a duration measured in years and should be sufficiently long-lived to allow diagnosis and surgical cure. These findings are further corroborated by the Gompertz function, according to which tumour growth follows a sigmoid curve where growth is slowest at the start and end of a growth period. 40 Taken together, these observations could explain why close-meshed follow-up examinations are highly effective in the prevention of thick melanomas. An important limitation of our work is the rather small size and focus on patients with SPMs. Although several studies have highlighted the biological similarity of first and second primary melanomas, we cannot exclude a covert selection bias which limits a generalization of our conclusions. Moreover, tumour biology and mutational spectrum of cutaneous melanomas depend on different UV-exposures in the populations and it has been shown that UVA-irradiation induces melanoma invasion. 41 As a consequence, the results of our German cohort may not necessarily be transferable to other parts of the world. On the other hand, the study is strengthened by the prospective documentation of follow-up examinations that provide far more objective and accurate information than patient interviews. This allowed us to determine the date of the last inconspicuous total body skin examination before the SPM diagnosis and to analyse the clinic-pathologic characteristics of thick SPMs.
In conclusion, this study provides evidence that fast-growing melanomas without opportunity of early detection are rare and cannot explain the stable incidence of thick melanomas. The fact that follow-up examinations enable a highly efficient diagnosis of SPMs early in their course (86.0% thinner than 1.00 mm) highlights the importance of close-meshed total body skin examinations in patient groups that are at high risk of first or multiple primary melanomas. Moreover, particular attention should be paid during follow-up to SPMs presenting as atypical lesions.
